(4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide | 1190244-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide
• 英文别名: (3S,4S)-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-4-methyl-3,4-dihydropyrazole-5-carboxamide
• CAS: 1190244-41-7
• 化学式: C₂₄H₂₇Cl₃N₄O
• 分子量: 493.864
• InChiKey: MAXRCXSLWTVPQO-AGQHMROBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide hydrochloride
  参考文献：
  名称：

  4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist

  摘要：

  本发明涉及4-甲基-4,5-二氢-1H-吡唑-3-甲酰胺及其药学上可接受的盐和溶剂。它进一步涉及以该化合物为活性成分的制药组合物，以及制备该化合物和组合物的过程和中间体。所述化合物是一种大麻素CB1中和拮抗剂，可用于预防和治疗进食障碍。

  公开号：

  EP2108643A1
• 作为产物：
  描述：

  (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carbonyl chloride 、 2,6-cis-dimethyl-1-amino-piperidine 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以71%的产率得到(4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist

  摘要：

  本发明涉及4-甲基-4,5-二氢-1H-吡唑-3-甲酰胺及其药学上可接受的盐和溶剂。它进一步涉及以该化合物为活性成分的制药组合物，以及制备该化合物和组合物的过程和中间体。所述化合物是一种大麻素CB1中和拮抗剂，可用于预防和治疗进食障碍。

  公开号：

  EP2108643A1

文献信息

• Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2151234A1

  公开（公告）日：2010-02-10

  The present invention relates to a pharmaceutical formulation comprising 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as racemate or (S)-enantiomer or mixtures thereof in a solid solution and/or solid dispersion.

  本发明涉及一种制药配方，其中包括5-(4-氯苯基)-1-(2,4-二氯苯基)-N-(顺-2,6-二甲基哌啶-1-基)-4-甲基-4,5-二氢-1H-吡唑-3-羧酰胺的混合物或(S)-对映体或它们的固溶体和/或固态分散体。
• PHARMACEUTICAL FORMULATION COMPRISING A CB1-RECEPTOR COMPOUND IN A SOLID SOLUTION AND/OR SOLID DISPERSION
  申请人：Soler Ranzani Luis

  公开号：US20110159086A1

  公开（公告）日：2011-06-30

  The present invention relates to a pharmaceutical formulation comprising 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as racemate or (S)-enantiomer or mixtures thereof in a solid solution and/or solid dispersion.

  本发明涉及一种药物制剂，其中5-(4-氯苯基)-1-(2,4-二氯苯基)-N-(顺-2,6-二甲基哌啶-1-基)-4-甲基-4,5-二氢-1H-吡唑-3-羧酰胺作为外消旋体或(S)-对映体或它们的混合物，以固态溶液和/或固态分散体的形式存在。
• 4-METHYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDE USEFUL AS A CANNABINOID CB1 NEUTRAL ANTAGONIST
  申请人：Vela Hernandez Jose Miguel

  公开号：US20110028517A1

  公开（公告）日：2011-02-03

  The present invention relates to 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide, and pharmaceutically acceptable salts and solvates thereof. It further concerns pharmaceutical compositions comprising this compound as active ingredient as well as processes and intermediates for preparing this compound and compositions. The referred compound is a cannabinoid CB1 neutral antagonist useful in the prophylaxis and treatment of food intake disorders.

  本发明涉及4-甲基-4,5-二氢-1H-吡唑-3-羧酰胺及其药学上可接受的盐和溶剂化物。此外，本发明还涉及以该化合物为活性成分的制药组合物，以及用于制备该化合物和组合物的过程和中间体。所述化合物是一种大麻素CB1中和剂，可用于预防和治疗食物摄入障碍。
• EP2282997A2
  申请人：——

  公开号：EP2282997A2

  公开（公告）日：2011-02-16
• [EN] 4-METHYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDE USEFUL AS A CANNABINOID CB1 NEUTRAL ANTAGONIST<br/>[FR] 4-MÉTHYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDE UTILE EN TANT QU'ANTAGONISTE NEUTRE DES CANNABINOÏDES CB1
  申请人：ESTEVE LABOR DR

  公开号：WO2009124950A2

  公开（公告）日：2009-10-15

  The present invention relates to 4-methyl-4, 5-dihydro-1H- pyrazole-3-carboxamide, and pharmaceutically acceptable salts and solvates thereof. It further concerns pharmaceutical compositions comprising this compound as active ingredient as well as processes and intermediates for preparing this compound and compositions. The referred compound is a cannabinoid CB1 neutral antagonist useful in the prophylaxis and treatment of food intake disorders.